{"id":"W4380730064","doi":"10.1007/s13555-023-00942-y","title":"Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"LEO Pharma; Allergan; Argenx; Sanofi Genzyme; Incyte; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Galderma; Ortho Dermatologics; Bristol-Myers Squibb; Eli Lilly and Company; Pfizer; National Psoriasis Foundation; Amgen","keywords":"Eczema Area and Severity Index; Medicine; Discontinuation; Atopic dermatitis; Adverse effect; Dermatology Life Quality Index; Clinical endpoint; Internal medicine; Body surface area; Quality of life (healthcare); Clinical trial; Dermatology; Disease","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001806279,0.0005631743,0.001366692,0.0001596604,0.000353956,0.0006170609,0.0003788822,0.0007129082,0.001625715],"category_scores_gemma":[0.001001268,0.0002755246,0.00135735,0.0001697605,0.0004016684,0.0005404027,0.000244619,0.002106037,0.0003990851],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004352097,"about_ca_system_score_gemma":0.0008810418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004798771,"about_ca_topic_score_gemma":0.001611881,"domain_scores_codex":[0.9995658,0.0002053764,0.00003232931,0.00006968928,0.00006476864,0.00006202183],"domain_scores_gemma":[0.9990126,0.000195453,0.0002430411,0.00007464418,0.000106794,0.0003673949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5172659,0.1219848,0.0909801,0.001896631,0.002845713,0.0009988933,0.001104961,0.002234651,0.0792444,0.0003542553,0.006524417,0.1745652],"study_design_scores_gemma":[0.2559748,0.6026167,0.1271261,0.0001352336,0.0008304471,0.001228761,0.0002382811,0.002286056,0.004618043,0.0002010558,0.004690067,0.00005446244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968178,0.001070975,0.0002629141,0.0001214928,0.00003051823,0.0007735425,0.0003759879,0.00002246484,0.0005241463],"genre_scores_gemma":[0.9954568,0.0008166828,0.0009627703,0.0006147672,0.00006407432,0.0008786411,0.0006660179,0.000009808112,0.0005302982],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001806279,"threshold_uncertainty_score":0.009552598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02961108722512346,"score_gpt":0.3179160238496889,"score_spread":0.2883049366245655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}